RxDoctor Payments Data

Diana Hickey, NP

Family · Bad Axe, MINPI 1184272528

Payments from drug & device makers

$636in general payments, 2019–2025

Across 24 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$149
  • Exact Sciences$131
  • Vifor Pharma, Inc.$125
  • Akebia Therapeutics Inc$70
  • AstraZeneca$29
  • Otsuka America Pharmaceutical, Inc.$27
  • plus $106 from 5 others

What the payments were for

  • Food & beverage$62298%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 60th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$180
Medicare patients
12
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$84,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$72,046
TrulicityDulaglutide59$59,482
OzempicSemaglutide33$31,703
EliquisApixaban19$29,570
JanuviaSitagliptin Phosphate31$28,997
XareltoRivaroxaban22$22,200
Tresiba Flextouch U-200Insulin Degludec31$19,788
MounjaroTirzepatide19$19,703
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,064
Ventolin HfaAlbuterol Sulfate69$4,038
Fluticasone Propionate HfaFluticasone Propionate14$3,548
Fenofibrate13$2,767
Albuterol Sulfate HfaAlbuterol Sulfate81$2,602
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$22$74,551100 claims
Novo NordiskOzempic$149$31,70333 claims
PfizerEliquis$25$29,57019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,657 family providers in Michigan.

Other family in Bad Axe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →